BPC-157 blocks amphetamine stereotypy and rescues haloperidol-induced catalepsy BPC-157 is anti-nociceptive in an incisional-pain model but if you need it in a pinch it counteracts morphines analgesia and lithium toxicity BPC-157 corrects basically any electrolyte problem in any direction: hyperkalemia, hypermagnesemia, and honestly you should just read this litany of various electrolyte disturbances that BPC-157 handles with ease BPC-157 reverses both atropine mydriasis and drug-induced miosis in the same rats and guinea pigs
Incorporating avocados into salads, spreads, or smoothies can be a delectable way to enhance your antioxidant defenses
My whole idea, my whole goal started from very early on because my mission was in life is just to be educated and to educate others
[1] GLP-1s remain covered for: BMI 40 (Class III/morbid obesity) Type 2 Diabetes (Mounjaro, not Zepbound) Major Adverse Cardiac Events history Employers who opt-in to add weight loss drug coverage California Medi-Cal Alert: GLP-1 Exclusion Effective January 1, 2026 If you have Kaiser through Medi-Cal, weight loss GLP-1 coverage is ending
Funding This work was supported by the Schissler Foundation Fellowship (to CB), the Center for Cancer Epigenetics Scholar Award (to CB and MF) and from the (i) National Institutes of Health: R21 NS093387 (to JC)
Pressure to bring down costs will continue to grow
